Thermo Fisher Scientific (TMO) beat Wall Street’s third-quarter estimates on Wednesday, October 21, and the stock barely moved. Shares were up about 1% at roughly $695 in afternoon trading. Adjusted EPS of $6.68 topped the $6.40 consensus, and revenue rose 9% to $12.14 billion with 6% organic growth, according to the company’s third-quarter release.
The flat reaction makes sense once you take the beat apart. About $0.15 of that EPS came from one-time tariff refunds, so more than half of the $0.28 beat won’t come back next quarter.
Where Thermo Fisher’s Beat Came From
On the earnings call, CFO Jim Meyer split the $0.26 of EPS upside against the company’s own guidance into three pieces: $0.08 from operations, $0.03 from currency, and $0.15 from tariff refunds that were never in the guidance. The refunds added about $60 million of adjusted operating income, or 50 basis points of margin.
Strip them out and the quarter shrinks:
- Adjusted EPS of about $6.53, a $0.13 beat (2%) instead of $0.28 (4.4%)
- EPS growth of about 13% instead of the headline 15%
- Margin expansion of about 70 basis points instead of 120 (adjusted operating margin was 24.5%, up from 23.3%)
The growth beat holds up better. Organic revenue ran about 2 points ahead of guidance, led by 10% organic growth in Laboratory Products and Biopharma Services. Management said part of that was Pharma Services work landing in the third quarter instead of the fourth, which is why fourth-quarter organic guidance stays at 4%.
The Raise Is Smaller Than It Looks
Thermo Fisher lifted its 2026 adjusted EPS guidance to $25.13 to $25.43. The midpoint moved up $0.15 to $25.28, and $0.05 of that is tariff money left over after about $40 million of extra fourth-quarter spending. Operations added $0.09. Full-year organic growth guidance rose to 4%.
Cash is the clean part of the report. Free cash flow reached $4.6 billion through September, up 39% from $3.3 billion a year earlier, and the full-year target rose to $7.0 billion to $7.5 billion.
TIKR Tracks 30 Analysts on Thermo Fisher. How Many Say “Buy”?
See the full breakdown of Buy, Hold, and Sell ratings on Thermo Fisher, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See Thermo Fisher’s Analyst Ratings
TMO Stock Has Already Priced the Recovery
At 26.15x forward earnings, Thermo Fisher trades above its five-year average of 23.64x and far from its 17.12x low. In May, with the stock near $473, it traded at about 18.6x.
Analysts have chased the price up. The mean price target climbed from about $591 in July to $690.62, which is level with the stock.
A June model run put fair value near $725 by the end of 2030. That’s only about 4% above today’s price, with four years still to go. The market has paid for the recovery in advance, and a 2% underlying beat gives it little reason to pay more.
The Date Thermo Fisher Holders Should Circle
February 2 is the next real test, when Thermo Fisher reports its fourth quarter and gives 2027 guidance. CEO Marc Casper has framed organic growth moving through a 3% to 6% range on the way back to 7%, which he called a normal year, sometime around late 2027 or early 2028.
At 26x forward earnings, the stock needs the top half of that range. A 2027 organic guide of 5% or better supports today’s multiple. One at 4%, matching this year’s organic revenue growth outlook, leaves TMO priced for growth that hasn’t shown up yet.
So what is Thermo Fisher stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what TMO stock could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Value Thermo Fisher Scientific Inc. for free→
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!
